Pierre Frères

696 total citations
24 papers, 445 citations indexed

About

Pierre Frères is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Pierre Frères has authored 24 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Pierre Frères's work include Cancer Immunotherapy and Biomarkers (5 papers), Glioma Diagnosis and Treatment (4 papers) and MicroRNA in disease regulation (4 papers). Pierre Frères is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Glioma Diagnosis and Treatment (4 papers) and MicroRNA in disease regulation (4 papers). Pierre Frères collaborates with scholars based in Belgium, Germany and Netherlands. Pierre Frères's co-authors include Guy Jérusalem, Claire Josse, Vincent Bours, Ingrid Struman, Nicolas Bovy, Stéphane Wenric, Michelle Lion, Joseph Martial, Sébastien P. Tabruyn and Marc Thiry and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Pierre Frères

23 papers receiving 440 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre Frères Belgium 10 310 259 71 54 42 24 445
Dana Hamam Canada 7 452 1.5× 416 1.6× 82 1.2× 13 0.2× 34 0.8× 12 586
Pradeep Chaluvally–Raghavan United States 12 344 1.1× 236 0.9× 133 1.9× 27 0.5× 117 2.8× 24 520
Xinghong Yao China 9 336 1.1× 209 0.8× 48 0.7× 10 0.2× 55 1.3× 22 468
Yu Liang China 11 1.0k 3.4× 551 2.1× 125 1.8× 37 0.7× 62 1.5× 20 1.2k
Alessandro Ciucci Italy 8 198 0.6× 65 0.3× 105 1.5× 81 1.5× 47 1.1× 8 348
Maura B. Cotter Ireland 8 315 1.0× 226 0.9× 109 1.5× 14 0.3× 25 0.6× 20 472
Jiajia Gao China 9 394 1.3× 304 1.2× 77 1.1× 17 0.3× 46 1.1× 13 501
Kenneth A. Bøtkjær Denmark 12 183 0.6× 173 0.7× 114 1.6× 9 0.2× 29 0.7× 15 351
Zenia Tiang Singapore 9 515 1.7× 343 1.3× 49 0.7× 93 1.7× 28 0.7× 16 663

Countries citing papers authored by Pierre Frères

Since Specialization
Citations

This map shows the geographic impact of Pierre Frères's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Frères with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Frères more than expected).

Fields of papers citing papers by Pierre Frères

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Frères. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Frères. The network helps show where Pierre Frères may publish in the future.

Co-authorship network of co-authors of Pierre Frères

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Frères. A scholar is included among the top collaborators of Pierre Frères based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Frères. Pierre Frères is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cousin, François, Thomas Louis, Pierre Frères, et al.. (2025). Machine Learning Model Integrating CT Radiomics of the Lung to Predict Checkpoint Inhibitor Pneumonitis in Patients with Advanced Cancer. Technology in Cancer Research & Treatment. 24. 2244085892–2244085892. 1 indexed citations
3.
4.
Tabatabai, Ghazaleh, Louisa von Baumgarten, Martin J. van den Bent, et al.. (2024). Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.. Journal of Clinical Oncology. 42(16_suppl). TPS2095–TPS2095. 3 indexed citations
5.
Richy, Florent, et al.. (2024). Treatment patterns and outcomes in patients with non-small cell lung cancer. Heliyon. 10(22). e40147–e40147. 1 indexed citations
6.
Simonelli, Matteo, Mario Caccese, Delphine Larrieu‐Ciron, et al.. (2023). CTIM-32. A PARALLEL COHORT PHASE 2 STUDY OF REGORAFENIB PLUS NIVOLUMAB FOR RECURRENT OR METASTATIC SOLID TUMORS: RESULTS IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) OR ANAPLASTIC ASTROCYTOMA (AA). Neuro-Oncology. 25(Supplement_5). v69–v70. 1 indexed citations
7.
Frères, Pierre, et al.. (2021). Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer. Case Reports in Oncology. 14(2). 972–976. 10 indexed citations
8.
Poulet, Christophe, Pierre Frères, Léon Mutesa, et al.. (2021). Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites. Scientific Reports. 11(1). 11698–11698. 7 indexed citations
9.
Frères, Pierre, et al.. (2021). [Immune-related adverse events].. RMLG. Revue médicale de Liège. 76(5-6). 403–407. 1 indexed citations
10.
Roth, Patrick, Thierry Gorlia, Jaap C. Reijneveld, et al.. (2021). EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology. 39(15_suppl). 2004–2004. 22 indexed citations
11.
Onesti, Concetta Elisa, Hélène Schroeder, Andrée Rorive, et al.. (2020). 1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium. Annals of Oncology. 31. S1007–S1007.
12.
Onesti, Concetta Elisa, Hélène Schroeder, Andrée Rorive, et al.. (2020). 1720P How do oncological patients perceive the COVID-19 pandemic? Experience from CHU Liège in Belgium. Annals of Oncology. 31. S1010–S1010. 1 indexed citations
13.
Frères, Pierre, Nassim Bouznad, Laurence Servais, et al.. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 18(1). 102–102. 56 indexed citations
14.
Wenric, Stéphane, Jean‐Hubert Caberg, Corinne Fasquelle, et al.. (2017). Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. Scientific Reports. 7(1). 17452–17452. 32 indexed citations
15.
Frères, Pierre, Marie Moonen, Claire Josse, et al.. (2016). [Cancer therapy-induced cardiotoxicity].. PubMed. 71(9). 382–387. 1 indexed citations
16.
Frères, Pierre, Stéphane Wenric, Corinne Fasquelle, et al.. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. 7(5). 5416–5428. 49 indexed citations
17.
Josse, Claire, et al.. (2015). BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer. 15(1). 181–181. 19 indexed citations
18.
Bovy, Nicolas, Pierre Frères, Olivier Nivelles, et al.. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. 6(12). 10253–10266. 142 indexed citations
19.
Josse, Claire, Bouchra Boujemla, Pierre Frères, et al.. (2015). Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer. 15(1). 755–755. 19 indexed citations
20.
Frères, Pierre, Joëlle Collignon, Christine Gennigens, et al.. (2010). Triple Negative Breast Cancer. The Cancer Journal. 16(6). 643–643. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dana Hamam Breakdown of academic impact, for papers by Pradeep Chaluvally–Raghavan Breakdown of academic impact, for papers by Xinghong Yao Breakdown of academic impact, for papers by Yu Liang Breakdown of academic impact, for papers by Alessandro Ciucci Breakdown of academic impact, for papers by Maura B. Cotter Breakdown of academic impact, for papers by Jiajia Gao Breakdown of academic impact, for papers by Kenneth A. Bøtkjær Breakdown of academic impact, for papers by Zenia Tiang
Rankless by CCL
2026